Medisun Precision Medicine Ltd., a development stage company, focuses on developing targeted therapies primarily in the United States. It is developing ACX-31, a program to deliver temozolomide, a chemotherapy drug in combination with BCNU directly to brain tumor sites; and BranchPoint, a microinjection brain catheter for use in the delivery of therapeutics to the human brain. The company has a collaboration agreement with DelMar Pharmaceuticals, Inc. to develop ACX-31; and a consulting agreement with Lim Development Group to develop and commercialize the BranchPoint device. The company was formerly known as Accurexa, Inc. and changed its name to Medisun Precision Medicine Ltd. in June 2017. Medisun Precision Medicine Ltd. was incorporated in 2012 and is based in Majuro, the Republic of the Marshall Islands.